| Identification | Back Directory | [Name]
abciximab | [CAS]
143653-53-6 | [Synonyms]
Reopro
CentoRx
Rheopro
Unii-X85G7936gv
Immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhCgamma1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3VkappahCkappa light chain |
| Hazard Information | Back Directory | [Uses]
Monoclonal antibody
(antithrombotic). | [Brand name]
ReoPro (Lilly). | [Clinical Use]
Antiplatelet agent:
Prevention of ischaemic cardiac complications
in patients undergoing percutaneous coronary
intervention
Short-term prevention of myocardial infarction
in patients with unstable angina not responding
to treatment or awaiting percutaneous coronary
intervention. | [Enzyme inhibitor]
This antithrombotic (MW = 47455 g/mol; CAS 143653-53-6; also known as Reopro?) consists of an immunoglobulin G1 Fab fragment from a chimeric human-murine monoclonal antibody directed against the human platelet glycoprotein IIb/IIIa receptor. Abciximab also facilitates the dispersal of newly formed platelet aggregates in vitro, by partially displacing fibrinogen from activated GPIIb/IIIareceptors. In vivo, abciximab may destabilize coronary thrombi by preventing aggregate formation and dispersing mural thrombi. Target(s): coagulation factor Xa, in presence of heparin; glycoprotein IIb/IIIa receptor. | [Drug interactions]
Potentially hazardous interactions with other drugs
Heparin, anticoagulants, antiplatelets and
thrombolytics: increased risk of bleeding. | [Metabolism]
Following IV administration, abciximab rapidly binds
to the platelet GPIIb/IIIa receptors, and remains in the
circulation for 15 days or more in a platelet-bound state.
Metabolism is via proteolytic cleavage |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
Wuhan Topule
|
| Tel: |
+86-02787215551 +86-19945035818 |
| Website: |
http://www.topule.com/ |
| Company Name: |
AntibodySystem
|
| Tel: |
027-65279366 18162686757 |
| Website: |
www.antibodysystem.com |
|